

FOR IMMEDIATE RELEASE

Theralase Balances Research Breakthroughs with Fiscal Responsibility

Toronto, Ontario – April 29, 2010 **Theralase Technologies Inc. (TSX-V: TLT)** announces fiscal 2009 financial results, demonstrating that breakthrough research combined with prudent management generates positive company and stock potential.

Astute management has put Theralase's administrative expenses for the twelve month period ended December 31, 2009 at \$992,742, an impressive **26% decrease** from the same period for 2008. This significant change is due primarily to reduction in administrative expenses, lower recruitment fees and improved account collection. Cash flows generated from operating activities (prior to net changes in other operating items) amounted to \$22,845 for 2009 compared to (\$597,974) for 2008, and are trending upwards due to increased revenues and decreased expenses.

Theralase Laser Technologies continues to maintain consistent growth while showing tremendous promise in use of its patented laser technology with its patented, light-activated photodynamic compounds (PDC's) for the **destruction of cancer cells**. Significant results of pre-clinical studies, in concert with Theralase's successful FDA approval record are key. Further success in this cancer pre-clinical research creates an unprecedented opportunity for Theralase to achieve real breakthroughs in technology and the potential to generate hundreds of millions of dollars in revenue, which would be positively reflected in both the price and liquidity of its stock.

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. states, "We are extremely encouraged by recent pre-clinical results in the quest for a successful treatment of solid-core tumours such as: prostate, brain and breast cancer. At Theralase, we've remained focused on this tremendous research, while remaining fiscally responsible, funding our work with the therapeutic laser aspect of our business."

Independent research, conducted at the University Health Network, recently demonstrated the superiority of the TLT proprietary laser over competitive laser and light-based systems evaluated in the production of nitric oxide. Nitric oxide is shown to increase capillary diameter, bringing oxygen and fuel to injured tissue and accelerating the healing process. TLT's technology increases production of nitric oxide in cells by a staggering **700%**. This is critical to the success of Theralase's therapeutic lasers, whose revenues fund their cancer treatment research.

The Theralase PDC research and development initiative is also partially funded by the Ontario Centre's of Excellence – Photonics Division. The complete, consolidated financial statements and MD&A for three and twelve months ended December 31, 2009 can be found at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, and viruses. To learn more about Theralase, contact Roger Dumoulin-White, President and CEO of Theralase Technologies at 1 866 843 5273 or rwhite@theralase.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.